<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    TrovaGene, Inc.

    TrovaGene, Inc.

    Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...

    Trovagene is a clinical-stage, oncology therape...

    Filing Type:    PU
    Interpace Diagnostics Group, Inc.

    Interpace Diagnostics Group, Inc.

    Interpace Diagnostics is focused on developing and commercializing molecular diagn...

    Interpace Diagnostics is focused on developing ...

    Filing Type:    PU
    Blueprint Medicines Corporation

    Blueprint Medicines Corporation

    Blueprint Medicines is a precision therapy company striving to improve human healt...

    Blueprint Medicines is a precision therapy comp...

    Filing Type:    PU
    Heska Corporation

    Heska Corporation

    Heska Corporation (NASDAQ: HSKA – News) manufactures, develops and sells advance...

    Heska Corporation (NASDAQ: HSKA – News) manuf...

    Filing Type:    PU
    T2 Biosystems, Inc.

    T2 Biosystems, Inc.

    T2 Biosystems, a leader in the development and commercialization of innovative med...

    T2 Biosystems, a leader in the development and ...

    Filing Type:    PU
    Tactile Systems Technology, Inc.

    Tactile Systems Technology, Inc.

    Tactile Medical is a leader in developing and marketing at-home therapy devices th...

    Tactile Medical is a leader in developing and m...

    Filing Type:    PU
    Immuron Limited

    Immuron Limited

    Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on o...

    Immuron Ltd is a publicly listed Australian bio...

    Filing Type:    PU
    Mustang Bio, Inc.

    Mustang Bio, Inc.

    Mustang Bio, Inc. (“Mustang”), a Fortress Biotech Company, is a clinical-stage...

    Mustang Bio, Inc. (“Mustang”), a Fortress B...

    Filing Type:    PU
    Heat Biologics, Inc.

    Heat Biologics, Inc.

    Heat Biologics a biopharmaceutical company that develops immunotherapies with the ...

    Heat Biologics a biopharmaceutical company that...

    Filing Type:    PU
    Scholar Rock Holding Corporation

    Scholar Rock Holding Corporation

    Scholar Rock is a biopharmaceutical company focused on the discovery and developme...

    Scholar Rock is a biopharmaceutical company foc...

    Filing Type:    PU
    Mustang Bio, Inc.

    Mustang Bio, Inc.

    Mustang Bio, Inc. (“Mustang”), a Fortress Biotech Company, is a clinical-stage...

    Mustang Bio, Inc. (“Mustang”), a Fortress B...

    Filing Type:    PU
    Syros Pharmaceuticals, Inc.

    Syros Pharmaceuticals, Inc.

    Syros is redefining the power of small molecules to control the expression of gene...

    Syros is redefining the power of small molecule...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.